The chief development officer of Corcept Therapeutics sold 20,000 shares of the biotech for $703,656 on Tuesday.
The transaction was executed as a direct open-market sale of option shares; no indirect entities were involved.
The executive reported holding stock options underlying 250,000 shares after the transaction.
These 10 stocks could mint the next wave of millionaires ›
On Tuesday, William Guyer, the chief development officer of Corcept Therapeutics (NASDAQ:CORT), exercised and immediately sold 20,000 shares through open-market transactions totaling approximately $703,656, according to an SEC Form 4 filing.
Metric | Value |
|---|
Shares sold (direct) | 20,000 |
Transaction value | $703,656 |
Post-transaction shares (direct) | 1,235 |
Post-transaction value (direct ownership) | $44,188.30 |
What is the derivative context of this transaction?
This event involved the exercise of 20,000 stock options immediately followed by sale of the resulting common shares on the open market, with no indirect vehicles or gifting components.
How did this transaction affect William Guyer’s direct ownership?
Direct common stock holdings declined from 21,235 shares to 1,235 shares, a reduction of 94.18% of his direct equity stake; however, he also reported holding stock options underlying 250,000 shares after the transaction.
What is the remaining equity exposure after this transaction?
After this sale, Guyer retains 1,235 directly held shares valued at approximately $44,188.
Metric | Value |
|---|
Price (as of market close Tuesday) | $35.18 |
Market capitalization | $3.94 billion |
Revenue (TTM) | $741.17 million |
Net income (TTM) | $106.11 million |
* 1-year performance is calculated using Tuesday as the reference date.
Corcept Therapeutics generates revenue primarily from Korlym, an FDA-approved therapy for Cushing’s syndrome, and is advancing a pipeline of selective cortisol modulators targeting metabolic, oncologic, and neuropsychiatric disorders.
The company operates a drug discovery, development, and commercialization model, monetizing proprietary therapies through direct sales and ongoing clinical development of new indications.
Its primary customers include healthcare providers and specialists treating patients with endocrine and oncology disorders in the United States.
Corcept Therapeutics is a mid-cap biotechnology company focused on the development and commercialization of therapies for severe endocrine and oncologic conditions. The company leverages expertise in cortisol modulation to address unmet medical needs, supported by a growing portfolio of proprietary drug candidates. Corcept’s established market presence in Cushing’s syndrome and its advancing clinical pipeline provide a foundation for continued growth and competitive differentiation in specialized therapeutic markets.
Corcept’s stock had been one of the market’s quiet winners for most of the past year before a sharp collapse on Dec. 31, following the FDA’s complete response letter for relacorilant; however, the Form 4 shows the transaction stemmed from an option exercise, not a reduction in long-term exposure. While Guyer’s direct common stock position fell sharply, his remaining equity exposure is overwhelmingly derivative, with options representing far more upside sensitivity than the small number of shares retained outright. That structure suggests portfolio management rather than a shift in outlook.
Fundamentally, Corcept entered the regulatory setback from a position of strength. Third-quarter revenue rose to $207.6 million, up from $182.5 million a year earlier, driven by continued growth in Korlym prescriptions. Management reaffirmed full-year revenue guidance of $800 million to $850 million and ended the quarter with $524 million in cash and investments, providing balance sheet flexibility even amid clinical uncertainty.
Ultimately, options-related selling amid a regulatory shock should not be conflated with a weakening core business. The real signal remains clinical execution and the path forward for relacorilant, not a single administrative liquidity event.
Form 4: A required SEC filing disclosing insider trades of company securities by officers, directors, or major shareholders.
Exercised (stock options): The act of converting stock options into actual company shares, usually by paying a set price.
Open-market transaction: Buying or selling securities on a public exchange rather than through private or internal company arrangements.
Direct holdings: Shares owned personally by an individual, not through trusts, funds, or other entities.
Option shares: Shares obtained by exercising stock options, typically granted as part of employee compensation.
Indirect entities: Organizations or accounts, such as trusts or funds, used to hold shares on behalf of an individual.
Gifting components: The transfer of shares to another party as a gift, rather than through sale or purchase.
Equity exposure: The value or proportion of a person’s investment in a company’s shares.
Outstanding shares: Total shares of a company that are currently owned by all shareholders, including restricted shares.
Clinical pipeline: A company’s portfolio of drug candidates in various stages of research and development.
Cortisol modulator: A drug designed to alter the body’s response to the hormone cortisol, often for therapeutic purposes.
TTM: The 12-month period ending with the most recent quarterly report.
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $479,476!*
Apple: if you invested $1,000 when we doubled down in 2008, you’d have $49,342!*
Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $482,451!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.
See the 3 stocks »
*Stock Advisor returns as of January 5, 2026
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Corcept Therapeutics. The Motley Fool has a disclosure policy.
Corcept Insider Transaction Explained After Shares Tumble 50% in One Day was originally published by The Motley Fool
